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Abstract: Long-term T cell-mediated protection depends upon the formation of a pool of memory cells
to protect against future pathogen challenge. In this review we argue that looking at T cell memory
from a dynamic viewpoint can help in understanding how memory populations are maintained
following pathogen exposure or vaccination. For example, a dynamic view resolves the apparent
paradox between the relatively short lifespans of individual memory cells and very long-lived
immunological memory by focussing on the persistence of clonal populations, rather than individual
cells. Clonal survival is achieved by balancing proliferation, death and differentiation rates within
and between identifiable phenotypic pools; such pools correspond broadly to sequential stages in
the linear differentiation pathway. Each pool has its own characteristic kinetics, but only when
considered as a population; single cells exhibit considerable heterogeneity. In humans, we tend
to concentrate on circulating cells, but memory T cells in non-lymphoid tissues and bone marrow
are increasingly recognised as critical for immune defence; their kinetics, however, remain largely
unexplored. Considering vaccination from this viewpoint shifts the focus from the size of the primary
response to the survival of the clone and enables identification of critical system pinch-points and
opportunities to improve vaccine efficacy.
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1. Introduction
The introduction of vaccines has had a revolutionary effect on human health and life expectancy
over the last 50 years. Despite these huge advances, many basic immunological questions about
how long-term immunological memory is maintained remain unanswered. While many successful
vaccines act primarily by generating antibodies, there is also a clear need for vaccines that generate
populations of highly-specific T cells, especially against infectious agents that successfully escape
antibody responses.
At its most basic mechanistic level, T cell vaccine efficacy can be defined as the ability of the
vaccine to generate large, effective, long-lived populations of memory T cells. In this paper we will
take a dynamic view of how long-term T cell memory may be generated and maintained in humans
and review the implications of a kinetic perspective for how we think about vaccine responses.
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2. Part I: Thinking Kinetically—How Long Is a Memory?
2.1. The Longevity of Immune Responses
The key desirable property of a vaccine response (or the desirable consequence of
natural-immunity) is longevity. Duration of protection varies widely from one vaccine to another, and
from one pathogen to another. However, for many vaccines and infections, immunity is remarkably
long-lived—indeed, frequently life-long. The yellow fever vaccine represents a good example; it now
appears that a single dose confers life-long immunity [1]. Similarly, influenza immunity can last for
decades. Very elderly people appeared to be protected from the 2009 H1N1 “swine flu” influenza
epidemic [2] by previous exposure to a structurally-similar strain which circulated widely following
the 1918 epidemic [3]. There may be differences in longevity between B-cell and T cell immunity.
For example, for smallpox, post-vaccination B-cell memory was found to be stable for more than
50 years, whereas CD4+ and CD8+ T cell memory declined slowly with a half-life of 8–15 years [4,5].
Nonetheless, the take-home message is the same: immune memory is remarkably long-lived.
2.2. The Paradox of Long-Lived Memory and Short-Lived Cells
How is such longevity achieved? The oft-repeated view is that long-term immune memory
results from the generation of “memory” cells, which intrinsically and individually have a long
lifespan. Such cells are often referred to as “long-lived memory-cells”, the emphasis being on the
longevity of the cells, rather than the memory. The problem with this paradigm is that it conflicts with
a large body of experimental data, all of which suggest that memory T cells have limited lifespans,
certainly considerably shorter than the lifespan of immunological memory itself. For both CD4+ and
CD8+ T cells, although memory T cell populations persist, the individual cells that comprise those
populations proliferate and die at a non-insignificant rate [6]. For B-cells, a similar pattern is seen,
memory cells having a faster turnover rate than naive cells, but there is a significant contrast in that
B cells provide long-term protection thanks to their progeny—long-lived plasma cells [7].
This concept of rapid memory cell turnover is supported by several lines of experimental
evidence. Already 25 years ago, it was imputed from the disappearance rates of CD45R0+ T cells with
chromosome damage [8]. More recently, studies with Ki67 staining have shown that memory T cells
have higher proliferation rates than naive T cells [9,10]. Finally, direct measurement of cellular lifespans
using in vivo stable isotope labelling has shown that memory T cells are much shorter-lived than their
naive counterparts in both mice and men, in both young and old, and are also much shorter-lived
than the immunological memory they convey [11–15]. The lifespan of a human memory T cell is of
the order of 30–160 days [12,13,15,16], in contrast to the typical half-life of human T cell memory of
8–15 years [1,4,5]. Longevity thus does not seem to be an intrinsic characteristic of circulating memory
T cells.
2.3. Resolving the Paradox—Short-Lived Cells Conferring Long Lived-Memory
One way to resolve this apparent paradox is to view cellular behaviour from a kinetic viewpoint.
As Michie et al. observed in 1992, “ . . . memory is maintained by long-lived clones rather than individual
cells with a long lifespan” [17]. The pivotal concept here is that it is the population that must be long-lived,
not necessarily the individual cell. Hence, we need to refer to “cells conferring long-lived-memory”, rather
than “long-lived memory cells”. This concept is widely accepted and very familiar to people studying
the dynamics of T cell memory but has been slow to be adopted into some areas of immunology.
The contrast between the static and kinetic view of memory can be illustrated by an example
from the history of the transfer of knowledge (Figure 1). When Ptolemy I Soter I wanted to capture
the current knowledge of the world in the 4th century BCE, he built the great library of Alexandria in
which the finest manuscripts of the day were stored. The memory was static; once the scroll was stored,
the information on it remained captured and immutable, but accessible for recall at a later date. This is
analogous to the static view of anamnestic immunity—in which memory is preserved in a population
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of long-lived cells, available for recall when needed. An alternative view is provided by African
tribal elders who preserve their communal memory by entrusting their truths to story-tellers and
singers, the Griots, who sing the stories of the tribe and pass them on to future generations. The story is
dynamic and can be retold in different contexts, but maintains its core elements through each retelling.
A dynamic model of immune memory may be more like the latter—stories of prior vaccine or pathogen
exposure being retold in the clonal replication of memory cells from one cellular generation to another.
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2.4. Are There Really No Long-Lived Memory-Cells? 
Of course, this does not exclude the possibility that some T cells really are long-lived. Two other 
scenarios deserve consideration, and neither is mutually exclusive with the kinetic model. The first 
is that there are long-lived memory T cells in the circulation—it is just that we have not identified 
them yet; the second is that long-lived memory cells exist, but occur primarily outside the circulation. 
2.5. Circulating Memory Cells 
In terms of circulating cells, in vivo stable isotope labelling experiments analyse events in bulk 
populations and hence theoretically may miss a relatively small subpopulation of long-lived cells 
masked by a majority of dividing cells. Interestingly, no studies have yet identified a phenotype that 
corresponds to a circulating long-lived memory T cell. It would be surprising if there were a 
subpopulation of long-lived cells with no such marker, although it is possible that the only markers 
are transcriptomic or epigenetic, rather than phenotypic [18].  
2.6. Tissue-Resident Memory 
The second scenario posits that long-term memory T cells do exist, but primarily reside outside 
the circulation. This is difficult to test using human in vivo data as most such studies rely on sampling 
blood. Although lymph-node T cells recirculate [19], other T cell populations, such as those in bone 
marrow or in non-lymphoid tissues may act as long-term resident memory. Recent studies have 
shown that there is a substantial pool of memory T cells in diverse non-lymphoid tissues, including 
skin, intestine and brain. These cells, which mostly express CD69, have a tendency to stay locally and 
not to recirculate, and have therefore been coined tissue-resident memory T cells (TRM) [20–22]. TRM 
cells are thought to be very important for efficient clearance of recurring infections at the port of 
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2.4. Are There Really No Long-Lived Memory-Cells?
Of course, this does not exclude the possibility that some T cells really are long-lived. Two other
scenarios deserve consideration, and neither is mutually exclusive with the kinetic model. The first is
that there are long-lived memory T cells in the circulation—it is just that we have not identified them
yet; the second is that long-lived memory cells exist, but occur primarily outside the circulation.
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intest e and brain. These cells, which mostly express CD69, have a tendency to stay loc lly and not to
recirculate, and have t erefore been coined tissue-re ident memory T cells (TRM) [20–22]. TRM cells
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are thought to be very important for efficient clearance of recurring infections at the port of pathogen
entry, and appear functionally superior to circulating memory T cells [20,21]. New vaccine strategies
are currently being developed to trigger such TRM responses, with promising results [20,23]. Very little
is known, however, about the mechanism by which such TRM cells are maintained. Since their virtual
absence in peripheral blood hampers the study of their turnover, one cannot exclude the possibility
that they reside as long-lived memory cells at multiple non-lymphoid locations.
Bone marrow also contains memory T cells (perhaps analogous to B-cell derived plasma cells).
In contrast to the anticipated role of TRM in other tissues—to provide local protection at sites of
pathogen entry—such bone-marrow memory T cells (TBM) are thought to contribute to systemic
memory [24]. Interestingly, in many respects the phenotype of TBM resembles that of TRM cells,
with relatively high expression of CD69, and low expression of S1P1 and Klf2 [25,26]. Although
some evidence implies that TBM may be genuinely long-lived and may thus represent an archive-like
repository of memory [25,27], other data suggest that the vast majority of TBM recirculate like other
memory T cells (as reviewed by Di Rosa et al. [26]). Importantly, if such cells are not travelling to
meet antigen, then antigen must be brought to them; in this respect circulating dendritic cells may
play a pivotal role [28]. However, to date, the lifespan of bone marrow memory cells has not been
quantified, nor has their contribution to the immune response following rechallenge.
Even if such truly long-lived memory T cells do exist, a kinetic model is still appropriate as
a paradigm for vaccine responses as the predominant pool of circulating memory cells is clearly in
a state of dynamic equilibrium. In the next section we will consider what a kinetic model of a vaccine
response might look like.
3. Part II—The Vaccine Response—A Kinetic Model
3.1. Thinking Phenotypically—Differentiation Pathways for Memory T Cells
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The conventional model for differentiation of both CD4+ and CD8+ T cell populations is a linear
differentiation pathway in which cells progress along an immunological “one-way-street”; cells do
not normally regress to a lower differentiation state (Figure 2) [30,32]. (Non-linear or alternative
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linear models have also been proposed [33] but are not discussed here; for full consideration see
Restifo et al. [34]) A vaccine response, like a natural infection, would be expected to add to these pools
in a sequential manner—i.e., TSCM first, then central memory (TCM), through effector memory (TEM) to
terminal effectors (TTE), including effector memory CD45 revertants (TEMRA—not shown in the figure)
which are more likely to be formed with repeated restimulation. We can thus think about memory in
phenotypic terms (Figure 3) and ask the questions: Which phenotypically-defined populations are
expanded, which are contracted, and when? Since phenotype correlates with function, the phenotypic
profile of the population will predict its functional attributes.
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in massive expansion followed by contraction of phenotypically-defined subpopulations (Figure 3).
Factors, such as local cytokine concentrations or ligand engagement, which modify these rates will
therefore have a critical impact on the relative size of the different memory compartments preserved at
the end of the acute vaccine response and this represents an opportunity to modulate the response.Vaccines 2017, 5, 5  6 of 12 
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It is clear fro the above discussion that signals that pro ote e ory cell proliferation and
survival must operate both within clones (primarily through TCR engagement) and across populations
(primarily via cytokines and co-receptors) [31]. Such signals determine the relative likelihood of cell
survival. It still remains the subject of debate whether the formation of a retained memory population is
the stochastic consequence of random events happening heterogeneously across T cell populations [36],
or results from the generation of a distinct population. The latter possibility is supported by work that
suggests that “cells destined to survive into the memory phase of the response can be identified at the effector
stage, referred to as memory precursors” [18]. Such cells manifest distinct transcriptional signatures and
epigenetic changes. The existence of such a priori definable populations does not, however, exclude
the possibility that they are generated stochastically rather than deterministically.
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4. Part III—Consequences of Thinking Kinetically about Vaccines
4.1. Rethinking the Target—Beyond ‘Bigger Is Better’
Considering vaccine responses in a dynamic context has several implications. Firstly, it can
be seen from the above arguments that the primary goal of a vaccine is not to stimulate the largest
possible number of acutely-responding cells, but rather to generate a long-lived population of high
avidity, functional clones with an appropriate phenotypic distribution. Much work developing better
adjuvants has focussed on increasing the size of the primary response, often used as a readout in
vaccine studies, but indices of long-term memory may be a better index of success. Of course the two
are not independent; larger primary responses tend to generate more memory cells [40], although the
size of the primary response is also critically determined by the frequency of reactive cells in the naive
repertoire [41].
It can also be seen from the dynamics of expansion and contraction that there may be greater
opportunities to “improve” a vaccine by improving retention of memory cells rather than by increasing
the magnitude of the initial response. For example, if one doubles the initial response, one may double
the later memory population (assuming proportionality), but if one reduces the loss of cells between
the acute response and the retained cell population by 2%, from 99.5% to 97.5%, the size of the final
long-term memory population will be increased five-fold. Hence, retention/survival rates of memory
cells may be more important to vaccine efficacy than the size of the primary response.
4.2. Focussing on Phenotype—and Beyond
A dynamic view also provides a framework within which optimal target phenotypic profiles
for protection may be defined. These profiles may then be pursued experimentally. There is
unlikely to be a single “best” pattern of response. Different pathogens may require different T cell
phenotype profiles for optimal control—for some, a TEM-biased response will be required, whereas
for others a TSCM or TCM biased response may be more favourable. For example, HIV protection
may require a predominantly TEM response [42] and this may be why CMV-based vectors, that
provide continuous ongoing antigen-stimulation, result in control of infection with SIV [43]. Varying
the strength, timing and duration of antigen exposure is one way to modify the balance between
activation, memory, senescence and exhaustion [44]. Further epigenetic programming may occur
even within cell populations that share a single phenotype; thus, repeated antigen exposure drives
TEM towards characteristic secondary, tertiary, and quaternary molecular signatures without further
phenotype change [45]. The opportunity to intentionally programme cells to acquire and retain
a specific phenotypic or molecular profile by the way a vaccine is delivered (dose, route, timing, etc.)
represents an important advance in vaccinology.
4.3. Room for Change
A kinetic model also offers a basis for conceptualising how existing populations may be
remodelled to accommodate new populations as they are added to the memory repertoire. Despite
massive clonal expansions and contractions, the size of the human total lymphocyte pool remains
remarkably constant throughout adult life. There are some global changes, of course; with advancing
age, the naive T cell pool tends to contract in concert with falling thymic output, while the memory T cell
pool expands slightly, but most new memory populations are accommodated within a constrained
envelope. It has been suggested that, as a result of the constraint on total memory cell numbers,
immunological memory for previously encountered antigens may be gradually lost when new memory
cells are recruited, a phenomenon known as memory attrition. However, studies in mice [46] as
well as recent investigations of acute human EBV infection, suggest that even dramatic acute CD8
T cell expansions can be accommodated without substantially depleting pre-existing memory for
heterologous infections [47]. Moreover, recent studies have shown that the TRM pool may be more
flexible than the circulating pool of TCM and TEM [48].
Vaccines 2017, 5, 5 8 of 12
If there is, in some sense, competition for “space” in the memory pool, then a dynamic system in
which clones are maintained by homeostatic proliferation may result in better retention of memory.
In a dynamic system, clone-size can change continually; hence where “space” is limited, the clone-size
may reduce but the clone persists. Conversely, in a static system (like a library), populations are less
plastic and the risk of losing the clone altogether may be greater. In view of their relatively short
lifespan [13], circulating TEM and TCM populations are likely to be most flexible [46]. By contrast, the
TRM pool appears to be less constrained and this feature may be associated with greater longevity of
individual TRM cells [29].
4.4. Dynamic Systems Offer Opportunities for Modulation
One property of dynamic systems is that they offer opportunity for modulation; small
changes in proliferation or death rates can result in large changes in T cell numbers. A good
example is the successful use of immune checkpoint blockade of the costimulatory CD28 pathway;
suppressing CD28 co-stimulation via CTLA-4 ligation limits the immune response by inducing
T cell apoptosis. Conversely, activating CD28 prevents apoptosis and supports T cell expansion
and differentiation [49,50]. Both effects have been harnessed therapeutically, for instance to prevent
transplant rejection and to promote anti-tumour responses, respectively. Other strategies such as
blockade of inhibitory receptors, interleukin-2 administration, regulatory T cell modulation, and
targeting of mTOR, have all been suggested as potential tools to enhance CD8 T cell immunity [51].
IL-15 appears to have a particular key-role in determining the proliferation and survival rates of
memory CD8+ T cells through an M-TOR dependent pathway [52]. In addition, knowledge of
factors limiting the responsiveness of T cell memory populations may allow enhancement of memory
responses. In the elderly, for example, it appears that P38 may be a crucial contributor to CD8 T cell
senescence and that its effects may be reversible [53]. All these effects can be viewed through a kinetic
prism by assessing whether their primary effects are on proliferation, phenotype-transition, function
or death.
4.5. Thinking Locally—Directing the Immune Response
Although much of our knowledge of human T cell immunity is derived from and targeted
towards circulating cells, it has become increasingly clear that local responses are pivotal in pathogen
protection and clearance. Recent studies have suggested that there are opportunities to optimise vaccine
efficacy by increasing immune protection at peripheral sites of pathogen entry [20,23,43]. Mucosal
vaccination specifically has been advocated as a strategy to protect against mucosa-acquired infections
such as herpes simplex, HIV, and influenza [54]. However, a dynamic model would emphasise that
local populations not only have their own equilibrium, but also exist in dynamic equilibrium with
systemic immune cells, hence the intriguing strategy of “prime and pull” in which a systemic prime
is followed by recruitment of activated T cells to a local site. In a murine model, Shin and Iwasaki
gave a conventional parenteral vaccination but followed it with local topical chemokine application
given during the effector phase; this single chemokine “pull” was sufficient to establish a long-term
population of tissue-resident memory CD8+ (but not CD4+) T cells within the vagina [55].
Generating TRM may thus represent a specific target for future vaccine strategies. Interestingly,
the effect of TRM cells extends beyond their immediate availability and epitope-specific effects at the
site of pathogen-entry; their presence also appears to create a "pathogen alert" state in the local tissue
environment, which allows skin TRM cells to contribute to protection against antigenically-unrelated
viruses [56].
4.6. Implications for Viral Latency
Finally, if memory T cells are in fact short-lived cells, this may have implications for models of
latency for viruses that reside in cells of the T cell lineage. For HIV infection, for example, there has
been much debate over the location and size of the persistent viral reservoir. It is often stated that the
Vaccines 2017, 5, 5 9 of 12
long-lived viral reservoir resides in long-lived cells and strategies to activate those cells out of “latency”
are being actively pursued. However, if a latent virus is passed on from cells of a dividing clone to
their progeny, persistence may in fact result from persistence of the clone, rather than persistence of
individual cells [57].
5. Conclusions
In this paper we have presented a kinetic view of T cell memory. Taking this view allows
fundamental questions in human vaccinology to be addressed from a fresh perspective. Central to this
approach is the appreciation that T cells operate as populations composed of diverse and heterogeneous
individual cells—“memory” is a system property generated by the behaviour of clonal populations
rather than a characteristic of individual cells. Of course some cells may be programmed to contribute
more to memory than others [18,31], but the overall effect is achieved by dynamic populations.
For human vaccinology, many questions remain unresolved. Most of our knowledge on humans
relates to circulating cells, because that is what we can sample; we need to know more about
tissue-resident and bone-marrow-resident cells, particularly in terms of their kinetics and longevity.
This is a field where animal data have led the way, but we need to know how best to use such animal
data to inform human immunology, not just in terms of inter-species translation [58], but also in terms
of real-world versus laboratory-environment. Memory responses are profoundly altered by life in
a microbe-rich environment, as shown by differences between “clean” laboratory mice and those either
living outside laboratories [59], or exposed to multiple pathogens [60]. We need to know if kinetic
modelling can assist in the development of optimal vaccination schedules which have largely been
based on empiric experimental data until now. One specific area of interest is the apparent need for
ongoing antigenic stimulation for protective responses to HIV, as shown in simian models with live
CMV-based vectors [42,43]. Might kinetic modelling allow us to hypothesise alternative approaches
that do not require human “infection” with a CMV-like vaccine? Our understanding of human T cell
memory has grown enormously through the characterisation of key phenotypic markers [30,32];
discovery of novel markers may further enhance our understanding of memory subsets. Finally, there
is clearly much more to be learnt from epigenetics and transcriptomics, particularly in terms of lineage
commitment [31,45].
Better understanding of the organisation and regulation of T cell responses will open up new
opportunities for modulation and modification of vaccine responses. As Kamphorst et al. observed:
“Increased knowledge on the cellular and molecular requirements for CD8 T cell activation has unveiled new
opportunities to directly modulate CD8 T cells to generate optimal responses.” [51]. We hope that this analysis
has demonstrated the value of viewing immune memory as a kinetically-based whole system-response.
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